| 000 | 00951 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250516214447.0 | ||
| 264 | 0 | _c20150109 | |
| 008 | 201501s 0 0 eng d | ||
| 022 | _a1473-5628 | ||
| 024 | 7 |
_a10.1097/MNM.0000000000000124 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeylergil, Volkan | |
| 245 | 0 | 0 |
_aResponse to the letter from Oude Munnink et al. _h[electronic resource] |
| 260 |
_bNuclear medicine communications _cJul 2014 |
||
| 300 |
_a786 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xchemistry |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdiagnosis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 1-Ring _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 700 | 1 | _aCarrasquillo, Jorge A | |
| 773 | 0 |
_tNuclear medicine communications _gvol. 35 _gno. 7 _gp. 786 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MNM.0000000000000124 _zAvailable from publisher's website |
| 999 |
_c23871440 _d23871440 |
||